Regulatory news
What the HHS Peptide Interim Access Notice Actually Says (and Doesn't)
Coverage of the HHS peptide policy has been loud. The notice that carries it is short. We read the text published in the Federal Register and list what it says, what it leaves to other documents, and what readers can still do before the comment period ends.
The notice in facts
| Item | What the notice says |
|---|---|
| Title | "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" |
| Issued by | Office of the Secretary, Department of Health and Human Services |
| Where | Federal Register, Vol. 91, No. 209, October 30, 2026, pages 68526 to 68527 (filed October 28) |
| Type | Notice of availability |
| Docket | HHS-OASH-2026-0496 (RIN 0910-ZD94) |
| Effective date | None stated separately; the notice says it is published "as of October 30, 2026" |
| Comments | "2 weeks after date of publication," through regulations.gov. That is about November 13; the notice does not give the date |
What it says HHS will and will not do
The notice says HHS "does not intend to take enforcement action" against a state-licensed pharmacy, federal facility or licensed physician compounding a drug product with a peptide bulk substance listed in Appendix A (source 1). It calls the policy interim, applying "while the list of bulk drug substances" under section 503A "is developed through rulemaking," and says future FDA rulemaking "may propose adding some or all of these peptides" to that list.
It also says HHS "may revisit application of this interim policy (in whole or in part)" if a problem arises, giving "a safety signal or product quality issue" as one example, and that the policy "does not establish any rights for any person and is not binding on HHS or the public."
Email sign-ups are paused.
What the notice says about safety and evidence
It states that compounded drugs are not FDA-approved, so the agency does not review their safety, effectiveness or quality before marketing, and that they "may pose risks to patients." It points to Pharmacy Compounding Advisory Committee meetings and to "significant interest" in peptides because approved products are lacking. It does not present clinical efficacy or safety data for the peptides.
What is not in the notice
The notice refers to peptides "found in Appendix A," but the published version does not list them, and it contains no numbered conditions. The electronic-access section points to a separate file named "appendix-b." Details people are discussing, such as the six named peptides and conditions on bulk sources and certificates of analysis, come from the full policy document and from law-firm and trade-press summaries, not from these two pages. We attribute those details to those sources and say so (sources 2 and 3). For the document-quality conditions in context, see our summary of the policy document.
One more wrinkle: the notice's Background section calls it a "draft" policy while its summary describes it as available. Anyone relying on it should check the full policy text on the HHS page named in the notice.
Who this does and does not cover
The policy covers licensed pharmacies, federal facilities and licensed physicians. It does not cover research-use-only material, and it does not change what a research-supply company may say or do. Our article on what "research use only" means covers that distinction.
Comments
The notice invites written comments on the docket HHS-OASH-2026-0496 through regulations.gov, two weeks after October 30 publication. Comments are public, so the date and the docket number are worth confirming on regulations.gov rather than relying on a summary, including this one.
Limits of this article
We read the Federal Register notice as published on govinfo.gov. We did not read the appendices in that version, because they are not in it. The six peptide names and the conditions are reported from secondary sources and could change if HHS revises the policy.
Sources
- HHS Office of the Secretary, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," Federal Register Vol. 91, No. 209, Oct. 30, 2026, FR Doc. 2026-22192: govinfo.gov
- Holland & Knight, "HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides" (Nov. 2026): hklaw.com
- AJMC, "5 Things to Know About HHS's Interim Peptide Compounding Policy" (Oct. 29, 2026): ajmc.com